α-PD-1 mediated immune checkpoint blockade is now first line therapy for melanoma and PD-L1+ lung cancer, and second line therapy for squamous cell carcinoma of the head and neck (SCC-HN), and other tumor types [1, 2]. The gene discussed is CD274; the disease is melanoma.